THYROCARENSEThyrocare Technologies LimitedMinimalNeutral
Announced Sat, 9 May · 12:36 IST

Thyrocare Technologies Limited has informed the Exchange about Copy of Newspaper Publication of Audited financial results for the quarter and year ended March 31, 2026

THYROCARE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-2.9%1-day move
₹486.00
prior close
₹488.90
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-1.0-0.1+0.3-0.8-2.9-1.6-3.3-5.1-6.7-2.3+7.4+7.6+4.5
Up moveDown movePending
AI summary

Thyrocare Technologies has published its audited financial results for Q4 and full year ended March 31, 2026. Total income from operations grew to Rs. 846.03 Crore in FY26 from Rs. 702.18 Crore in FY25, a 20% increase. Profit After Tax nearly doubled to Rs. 162.85 Crore from Rs. 90.75 Crore in the previous year. EBITDA improved significantly to Rs. 217.65 Crore versus Rs. 146.88 Crore. EPS for the year stands at Rs. 10.27 compared to Rs. 5.70 in FY25. The Board has recommended a final dividend of Rs. 7 per share for FY 2025-26. The statutory auditors have issued an unmodified audit opinion on these results.

Likely market impact

Strong financial performance with near-doubling of profits signals solid execution. The 20% revenue growth and improved margins are positive for shareholders. The dividend declaration reinforces confidence in the company's cash generation ability.